Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein.
MAE, S., NS, K., OEE, A., AF, R., & RM, F. (2026). Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein.. Endocrine regulations. https://doi.org/10.2478/enr-2026-0019
MAE S, NS K, OEE A, AF R, RM F. Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein.. Endocrine regulations. 2026; doi: 10.2478/enr-2026-0019
MAE S, NS K, OEE A, et al. Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein.[J]. Endocrine regulations. 2026. DOI: 10.2478/enr-2026-0019.
@article{mae2026,
author = {Shalash MAE and Kandil NS and Alsaadany OEE and Radwan AF and Fathalla RM},
title = {Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein.},
journal = {Endocrine regulations},
year = {2026},
doi = {10.2478/enr-2026-0019},
note = {PMID: 42672130},
}
TY - JOUR AU - Shalash MAE AU - Kandil NS AU - Alsaadany OEE AU - Radwan AF AU - Fathalla RM TI - Unmasking silent atherosclerosis in type 2 diabetes: the emerging role of adipocyte fatty acid-binding protein. T2 - Endocrine regulations PY - 2026 DO - 10.2478/enr-2026-0019 AN - PMID:42672130 ER -
Objectives. Atherosclerosis contributes to higher mortality and morbidity in people with diabetes. Preventing future complications largely depends on the early detection of imminent atherosclerosis. This study aimed to explore the relationship between the subclinical atherosclerosis measured by carotid intima-media thickness (CIMT), ankle-brachial index (ABI), and circulating levels of adipocyte fatty acid-binding protein (AFABP) in individuals with type 2 diabetes mellitus (T2DM). Methods. A total of 80 participants evenly divided into two groups: 40 newly diagnosed patients with T2DM and 40 healthy controls. Patients with T2DM had no prior history or clinical signs of macrovascular complications, such as coronary artery disease, cerebrovascular stroke or peripheral artery disease. Serum total cholesterol, triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), fasting plasma glucose (FPG), and glycated hemoglobin (HbA1c) were measured. Plasma AFABP levels were determined using a human enzyme-linked immunosorbent assay (ELISA) kit. ABI was assessed using a sphygmomanometer with a cuff that fits the limb's circumference and a portable Doppler device. Doppler ultrasound of the carotid artery was used to measure CIMT. Results. In patients with T2DM, circulating AFABP levels were significantly higher than those in healthy subjects (p=0.007). Multivariate regression analysis indicated that AFABP is the only independent factor influencing the maximum CIMT (β=0.004, 95% CI: 0.001-0.007, p=0.017). Conclusion. Plasma AFABP level could serve as a biomarker for early diagnosis of atherosclerosis in patients with T2DM.